Treatment of unresectable locally advanced or metastatic bladder cancer has remained relatively unchanged since the early 1990s; chemotherapy regimens are still the mainstay of treatment. However, following the 2016-2017 FDA approvals of the PD-L1 inhibitor Tecentriq (Roche/Genentech) and the PD-1 inhibitor Opdivo (Bristol-Myers Squibb) for platinum-treated patients (i.e., second and later lines), immune checkpoint inhibitors are revolutionizing the treatment algorithm for this indication.

Questions Answered:

  • What are the treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?
  • What attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?
  • What are the prevailing areas of unmet need and opportunity in unresectable locally advanced or metastatic bladder cancer?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new drug for unresectable locally advanced or metastatic bladder cancer?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in January 2017

Key companies: Bristol-Myers Squibb, Eli Lilly, Roche/Genentech

Key drugs: Tecentriq, Javlor, gemcitabine


Related Reports

Bladder Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Bladder Cancer - Landscape & Forecast - Disease Landscape & Forecast

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically b...

View Details

Bladder Cancer | Disease Landscape and Forecast | G7 | 2020

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically b...

View Details